1302 Stock Overview
An investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for 1302 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
LifeTech Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.55 |
| 52 Week High | HK$2.07 |
| 52 Week Low | HK$1.24 |
| Beta | 1.23 |
| 1 Month Change | 8.39% |
| 3 Month Change | 8.39% |
| 1 Year Change | -19.69% |
| 3 Year Change | -32.02% |
| 5 Year Change | -11.93% |
| Change since IPO | 520.00% |
Recent News & Updates
Recent updates
Investors Can Find Comfort In LifeTech Scientific's (HKG:1302) Earnings Quality
May 02
Market Participants Recognise LifeTech Scientific Corporation's (HKG:1302) Earnings Pushing Shares 29% Higher
Mar 06LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump
Oct 02Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E
Jul 05LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear
Apr 25What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You
Dec 25Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled
Nov 28At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?
Nov 03Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
Aug 17Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?
Jul 18Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
May 05Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return
Oct 14There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital
Jul 15Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?
Jun 30A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)
Jun 15Returns At LifeTech Scientific (HKG:1302) Are On The Way Up
Apr 03Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
Mar 15Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?
Jan 22Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital
Dec 19Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today
Dec 06Is LifeTech Scientific (HKG:1302) A Risky Investment?
Nov 20An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued
Oct 12The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence
Sep 13Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?
Aug 28What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?
Aug 13LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business
Jun 08Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
May 26Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?
May 11LifeTech Scientific (HKG:1302) Could Easily Take On More Debt
Mar 31Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%
Feb 21Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?
Jan 26Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 13
Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?
Nov 25Shareholder Returns
| 1302 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -1.3% | -0.3% | 3.4% |
| 1Y | -19.7% | 6.0% | 13.0% |
Return vs Industry: 1302 underperformed the Hong Kong Medical Equipment industry which returned 6% over the past year.
Return vs Market: 1302 underperformed the Hong Kong Market which returned 13% over the past year.
Price Volatility
| 1302 volatility | |
|---|---|
| 1302 Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 9.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1302 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1302's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,395 | Yuehui Xie | www.lifetechmed.com |
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. The company’s products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers.
LifeTech Scientific Corporation Fundamentals Summary
| 1302 fundamental statistics | |
|---|---|
| Market cap | HK$7.18b |
| Earnings (TTM) | HK$240.72m |
| Revenue (TTM) | HK$1.41b |
29.8x
P/E Ratio5.1x
P/S RatioIs 1302 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1302 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.30b |
| Cost of Revenue | CN¥322.26m |
| Gross Profit | CN¥981.44m |
| Other Expenses | CN¥759.05m |
| Earnings | CN¥222.39m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.048 |
| Gross Margin | 75.28% |
| Net Profit Margin | 17.06% |
| Debt/Equity Ratio | 0% |
How did 1302 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 02:02 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LifeTech Scientific Corporation is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Gao | China International Capital Corporation Limited |
| Hanqing Zhu | Guosen Securities Co., Ltd. |
| Yidong Zhang | Industrial Securities Co. Ltd. |